s12931-014-0098-x 1465-9921 Research <p>Nebulized perflubron and carbon dioxide rapidly dilate constricted airways in an ovine model of allergic asthma</p> El Mays Y Tamer mtyel@ucalgary.ca Choudhury Parichita choudhur@ualberta.ca Leigh Richard rleigh@ucalgary.ca Koumoundouros Emmanuel emmanuel@unimelb.edu.au Van der Velden Joanne van@unimelb.edu.au Shrestha Grishma shresthg@tcd.ie Pieron A Cora capieron@solaeromed.com Dennis H John jdennis@solaeromed.com Green HY Francis fgreen@ucalgary.ca Snibson J Ken ksnibson@unimelb.edu.au

Airway Inflammation Research Group, Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada

Centre for Animal Biotechnology, University of Melbourne, Melbourne, VIC, Australia

Lung Health Research Centre, University of Melbourne, Melbourne, VIC, Australia

SolAero Ltd, Calgary, AB, Canada

Department of Pathology & Laboratory Medicine, HRIC 4AC62 3280 Hospital Drive N.W, Calgary T2N 4Z6, AB, Canada

Respiratory Research 1465-9921 2014 15 1 98 http://respiratory-research.com/content/15/1/98 10.1186/s12931-014-0098-x
1 4 2014 13 8 2014 16 9 2014 2014 El Mays et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Asthma Novel treatments Sheep model Allergic airway disease Carbon dioxide Perflubron

Abstract

Background

The low toxicity of perfluorocarbons (PFCs), their high affinity for respiratory gases and their compatibility with lung surfactant have made them useful candidates for treating respiratory diseases such as adult respiratory distress syndrome. We report results for treating acute allergic and non-allergic bronchoconstriction in sheep using S-1226 (a gas mixture containing carbon dioxide and small volumes of nebulized perflubron). The carbon dioxide, which is highly soluble in perflubron, was used to relax airway smooth muscle.

Methods

Sheep previously sensitized to house dust mite (HDM) were challenged with HDM aerosols to induce early asthmatic responses. At the maximal responses (characterised by an increase in lung resistance), the sheep were either not treated or treated with one of the following; nebulized S-1226 (perflubron + 12% CO2), nebulized perflubron + medical air, 12% CO2, salbutamol or medical air. Lung resistance was monitored for up to 20 minutes after cessation of treatment.

In additional naïve sheep, a segmental bronchus was pre-contracted with methacholine (MCh) and treated with nebulized S-1226 administered via a bronchoscope catheter. Subsequent bronchodilatation was monitored by real time digital video recording.

Results

Treatment with S-1226 for 2 minutes following HDM challenge resulted in a more rapid, more profound and more prolonged decline in lung resistance compared with the other treatment interventions. Video bronchoscopy showed an immediate and complete (within 5 seconds) re-opening of MCh-constricted airways following treatment with S-1226.

Conclusions

S-1226 is a potent and rapid formulation for re-opening constricted airways. Its mechanism(s) of action are unknown. The formulation has potential as a rescue treatment for acute severe asthma.

1 Background

Asthma is a common chronic disorder characterized by airway hyper-responsiveness, bronchial smooth muscle hypertrophy, increased mucus secretion, and airway inflammation 1 , 2 on a background of airway wall remodelling and mucous plugs 3 , 4 . Asthma is triggered by many factors such as allergens (e.g., pollen, pet dander), irritants (e.g., smoke), drugs, cold, exercise 5 , and upper respiratory tract infections 6 . Based on recent trends, the worldwide prevalence of asthma may increase from 300 million individuals currently to 400 million individuals by 2025 7 . Healthcare costs of asthma are considered to be among the highest associated with chronic disease 8 , 9 . In Canada, 59% of asthma patients treated in general practice are estimated to have uncontrolled disease 10 . Inhaled short acting β2-agonists represent the most common front-line emergency department treatment for acute exacerbations due to their well-known rapid bronchodilatory effect 11 13 β2-agonists, while generally considered safe may have significant side effects 14 and approximately one fifth to one third of patients do not respond to front-line treatment with short acting β2-agonists and ultimately require hospitalisation 15 . Furthermore, a clinically significant proportion of asthma patients are refractory to conventional treatments, posing a challenge for their management 16 . A new class of bronchodilators working through a different mechanism would be a useful addition for treating acute asthma.

In acute severe asthma, conventional treatment with inhaled β2 agonists may no longer be effective 11 13 , as the therapeutic aerosol may be unable to penetrate airways obstructed by mucous plugs 4 , increasing the risk of sudden death 17 . Emergency treatment for asthma includes mechanical ventilation 15 which may cause injury (barotrauma) to the ventilated segments of the lung 18 . Hence, a rapid non-invasive treatment for severe, life-threatening asthma is needed.

Inhaled carbon dioxide is a known bronchodilator for many mammalian species 19 . Hypercapnia has long been known to relax airway smooth muscle in vitro 20 , 21 , whereas hypocapnia causes airway smooth muscle contraction 22 . Hyperventilation is a well known trigger of asthma 23 . Studies by Fisher et al. 24 and Mc Fadden et al. 25 indicate that low alveolar PCO2 (PACO2) may be associated with an increase in airway tone in asthmatic patients. By contrast hypercapnia (induced by a short circuiting CO2 absorber) has been shown to reduce airway resistance in both healthy and asthmatic subjects 26 . Finally a study reported by Fisher and Hansen 27 showed that inhalation of 6% CO2 over 4–5 minutes relieved exercise induced airflow obstruction in young atopic asthmatics at rest and during exercise.

Perfluorooctylbromide (perflubron) is a chemically inert perfluorocarbon (PFC). It has a high solubility for respiratory gases such as CO2 and O2 and a low surface tension compatible with endogenous airway surfactant 28 30 . It has been used in total and partial liquid ventilation studies for treatment of ARDS 28 . In addition, perflubron has been shown to reduce pulmonary inflammation and injury through a variety of actions 28 , 31 33 . The high density and low surface tension of perflubron should also facilitate the penetration of obstructed airways and re-expansion of collapsed lung 34 .

There are no reported studies of PFC use in asthma. However, its properties of gas transport for CO2 and O2, low interfacial tension at the PFC-mucus interface, low toxicity and anti-inflammatory properties 31 33 , 35 make it a good candidate as a rescue therapy in life threatening acute asthma. Recently perflubron aerosols have been used to successfully treat acute lung injury in an animal model 36 , 37 .

The major challenge for treating acute severe asthma is to open constricted airways rapidly enough to allow delivery of conventional medication to the diseased airways.

In this study we show that inhaled nebulized perflubron + CO2 (S-1226) rapidly opens constricted airways in an ovine model of allergic asthma using house dust mite as allergen 38 , 39 .

2 Methods

2.1 Experimental sheep

Female merino-cross farm-reared sheep aged 6 months were used in the experiments described here. After the sensitisation procedures (described below), sheep were transported to Animal House Facility at Veterinary Science, Parkville, Australia where they were kept in indoor pens for all the procedures described in this report. On arrival at the Animal House Facility all sheep were treated with an antihelminthic to ensure that they were parasite-free.

All experimental protocols used in this study were approved by the Animal Experimentation Ethics Committee at the University of Melbourne.

2.2 Drug source

Acetyl-β-methylcholine chloride (MCh) was from Sigma-Aldrich, Stenhein, Germany and salbutamol sulphate solution was purchased from GSK Pty Ltd Australia. Gas mixture (12% CO2 + 21% O2+ balance N2) was from CIG Pty Ltd Australia.

2.3 Characterization of nebulized perflubron

Characterization of perflubron delivered by the Sidestream nebulizer was conducted under cGMP conditions at SolAero Ltd laboratory. Methods to characterize perflubron aerosol were adapted from regulatory methods embodied in the European Nebulizer Standard 40 . The unique nature of perflubron required adaptation of methods including incorporation of trace quantities (5%) of a perflubron compatible non-volatile PFC which could be assayed gravimetrically to determine both aerosol output as well as particle size distributions. Aerosol output was determined using a breath simulation (500 mL at 15 cycles per minute) and collecting released aerosol representing the ‘inhaled aerosol’ on a pre-weighed 3M electrostatic filter, subsequently allowing volatile perflubron to dissipate and quantitatively weighing the non-volatile PFC component. The residual weight gain was then used to back calculate the original amount of deposited aerosol. Pre- and Post- weights of nebulizers provided the gross perflubron emitted, from which the analyzed aerosol proportion could be subtracted to estimate the proportion of perflubron in the vapor phase. Aerosol size was determined using a Marple 298X cascade impactor equipped with pre-weighed GF/A filters from which the non-volatile aerosol residue was similarly gravimetrically determined to quantify size fractions.

2.4 House dust mite (HDM) sensitization and airway challenges

Sheep 6 months of age were subcutaneously sensitized with 50 μg house dust mite (HDM) extract (Dermatophagoides pteronyssinus; CSL Ltd, Parkville, VIC, Australia) mixed 1:1 in aluminum hydroxide [Al(OH)3] adjuvant. Injections of 1 ml HDM / Al(OH)3 were given on three occasions at 2 week intervals 38 . Levels of HDM-specific IgE (IgE-HDM) were determined by enzyme-linked immunosorbent assay (ELISA) of serum samples obtained from animals immediately prior to, and 7 days after, HDM sensitization 38 , 41 . Sheep were only selected for use in the study if they had increased levels of HDM-specific IgE (IgE-HDM) ≥2-fold above pre-sensitization values.

To induce pulmonary sensitization to HDM, all sheep were given three inhalation challenges of aerosolised HDM (1 mg/ml in 5 ml of phosphate buffered saline). Lung function was recorded for one hour directly after the aerosol HDM challenge. HDM aerosols were generated with a medical nebulizer (Vitalair RapidNeb, Allersearch, Vermont, Australia). The nebulizer was connected to a dosimeter system consisting of a solenoid valve and a source of compressed air (20 psi). The output of the nebulizers was directed into a T-piece with one arm connected to the inspiratory port of a mechanical ventilator (Intermed Bear 2 – Adult Volume Ventilator, Bear Medical Systems, Inc., Riverside, CA). HDM challenges were delivered at a tidal volume of 500 mL and a rate of 20 breaths per minute for 10 minutes.

2.5 Measurement of lung function

Data on lung function were obtained from all sheep using established techniques 42 . Briefly, pressures and flow were acquired from conscious unsedated sheep using a National Instruments Data Acquisition (DAQ) system with a Virtual Instrument programmed with Lab View® (National Instruments, Austin, USA). The sheep were restrained in a body sheath and head restraining harness tethered to a custom-made animal trolley. To measure oesophageal pressures, a balloon pressure catheter was advanced through one nostril into the lower esophagus. To assess tracheal pressures throughout the respiratory cycle a cuffed endotracheal tube was placed into the trachea and then a side-hole catheter was advanced 2 cm past the distal end of the endotracheal tube. The oesophageal and tracheal catheters were connected to differential transducers (Gaeltec 8 T, Gaeltec Ltd, Dunvegan, Scotland) to measure oesophageal pressure (Poes) and airway pressures (Paw) respectively. Transpulmonary pressure (Pl) was obtained from Poes with respect to Paw. Airflow was measured via a pneumotachograph (Hans Rudolph Inc, Kansas City, USA) attached to the proximal end of the endotracheal tube. Calibration and synchronization of the gas transducers and pneumotachograph were performed as described previously 43 , 44 . Lung dynamics were determined by a modified Mead-Whittenberger method 45 . Breath by breath analysis of flow and pleural pressure (Ppl) was used to determine lung resistance (RL) from an average of five breaths. Data from breaths which differed by more than 20% in volume and more than 10% of the breathing rate were rejected. Acquisition and detailed analysis of pulmonary physiological data were performed on customized Lab View software developed by Koumoundouros et al. 42 .

2.6 Treatment delivery

Treatments with nebulized S-1226, nebulized perflubron and nebulized salbutamol were generated with a Sidestream® nebulizer (Philips Respironics). The nebulizer was connected to a dosimeter system consisting of a solenoid valve and a source of compressed (20 psi driving pressure) gas mixture (12% CO2, 21% O2 and 67% N2) for S-1226 or compressed medical air (21% O2 and 79% N2) for perflubron and salbutamol. Treatments were delivered at a tidal volume of 500 mL and a rate of 20 breaths per minute for 2 minutes. Treatments with CO2 alone and medical air were performed following the same protocol but with an empty nebulizer.

2.7 HDM challenge followed by treatment

Sheep (previously HDM sensitized) were challenged with HDM aerosols to induce early phase asthmatic responses. At the peak of these responses (characterised by an increase in lung resistance), the sheep were treated for two minutes with one of six treatment groups listed below. Lung resistance was monitored up to 20 minutes following cessation of treatment.

1- S-1226: Nebulized perfluorooctylbromide (perflubron) generated using a Sidestream® nebulizer (Philips Respironics) and driven by a compressed gas mixture containing 12% CO2, 21% O2 and balance N2.

2- CO2 alone: Inhalation of a gas mixture containing 12% CO2, 21% O2 and balance N2.

3- Perflubron: Nebulized perflubron driven by compressed medical air.

4- Salbutamol (1 mg/ml): Nebulized salbutamol driven by compressed medical air.

5- Medical air: Inhalation of medical air

6- No treatment: room air

2.8 Video bronchoscopy

An unsensitised sheep was used in separate experiments to visually assess the airway response to inhaled S-1226. Real time video recordings were taken with a bronchoscope digital camera following methacholine challenge. To insure that the same airway was recorded throughout the procedure, the upper region of the airway was tattooed by injecting tissue dye using a transbronchial needle. The airway was then pre-contracted with an aerosol of methacholine (MCh) delivered via a Trudell Ltd Pty bronchoscope catheter, inserted into the biopsy port of the bronchoscope. Doubling doses of methacholine were nebulized directly into the lung segment (0.009, 0.018, 0.037 w/v) for 30 seconds with a 2 minute interval between methacholine doses until the airway was maximally constricted. The airway was then treated with nebulized S-1226 delivered through a Trudell Pty Ltd bronchoscope catheter and the effects video recorded in real time. If the airway re-constricted, second and third treatments were administered.

2.9 Data analysis

In each experiment several intervals were analysed: Baseline, HDM-induced early phase response, and three post-treatment periods (immediately, 1–10 minute and 10 to 20 minutes after treatment cessation). Means were calculated for each interval and treatment effect was expressed as percent decline of lung resistance.

Analysis of variance (ANOVA) was performed over each time interval to determine if any of the treatment groups performed better than any other. A two tailed Dunnett’s post-hoc test was performed. This involved separate analyses addressing two distinct questions. The first: is S-1226 superior to no treatment, medical air (negative control) or salbutamol (positive control). Secondly to determine which component of S-1226, CO2 or perflubron contributed greater to its efficacy. Tests were performed using GraphPad Prism version 5.00 and R version 3.1.1 for windows. A p-value ≤ 0.05 was considered significant.

3 Results and discussion

3.1 Characterization of nebulized perflubron

Results from characterization of nebulized perflubron are summarized in Table 1. The mean rate of perflubron delivered was 598 mg/minute, of which some 203 mg/minute consisted of aerosol with the remaining 395 mg/minute was estimated to be in vapor form – thus the majority (approximately 2/3 of the nebulized perflubron) was delivered in vapor form. The perflubron which was delivered in aerosol form demonstrated a relatively small particle size distribution, with a Mass Median Aerodynamic Diameter (MMAD) of 1.1 um, with a Geometric Standard Deviation (GSD) of 2.5 (Table 1). The perflubron aerosol size distributions obtained from the Sidestream nebulizer are shown in Figure 1.

<p>Table 1</p>

Nebulized perflubron

Aerosol size

Sidestream venturi CLOSED

Nebulizer flow rate L/min

Inhaled perflubron aerosol 1 minute mg

Inhaled perflubron Vapor 1 minute mg

Inhaled Total perflubron aerosol + vapor 1 minute mg/min

MMAD μm

GSD

Nebulized perflubron was characterized in two separate experiments (exp#1 and exp#2) using compressed gas flow rate of 8.5 L/min through a Sidestream nebulizer with active venturi closed. Nebulized perflubron liquid was determined to partition into aerosol and vapour states, with the vapour being the predominant physical form (means: 395 mg/min vapour vs 203 mg/min aerosol). The droplet size of the aerosolized perflubron component was further examined and fractionated using a Marple 298X cascade impactor. The nebulized perflubron aerosol distribution curve showed near log normal symmetry (see normative distribution, Figure 4) having a Mass Median Aerodynamic Diameter (MMAD) of 1.1 um, and a Geometric Standard Deviation (GSD) of 2.5.

Exp#1

8.5

208

392

600

1.1

2.4

Exp#2

8.5

198

399

597

1.1

2.6

Characterization of nebulized perflubron using the Sidestream (venturi closed)

<p>Figure 1</p>

Sidestream nebulizer aerosol size distribution.

Sidestream nebulizer aerosol size distribution. Aerosol size is on the X-axis is plotted against the normative and cumulative underside aerosol distributions. The blue boxes profile the normative size distribution of nebulized perflubron, the near symmetry suggests a log-normal distribution of aerosol particles. The red squares plot the same data but as a cumulative size distribution of particle size against cumulative undersize %. The cumulative size distribution is used to interpolate the MMAD as the particle size at 50% of the cumulative mass – in this case the MMAD is 1.1 um. The Geometric Standard Deviation (GSD) of the MMAD is calculated using the intercepts at 15.8% and 84.1% (approximated by grey lines in Figure) using the formula GSD = sq rt (size 84.1um / size 15.8 um).

The characterization of nebulized perflubron demonstrated that the majority of the nebulized perflubron existed in the vapor form while the remaining proportion of aerosol existed as a relatively fine aerosol with an MMAD of 1.1 um. We infer that perflubron as vapor and aerosol, as well as CO2 gas component of inhaled S-1226, would rapidly distribute throughout the respiratory tract.

3.2 HDM challenge followed by treatment

Sensitized and HDM challenged sheep treated with S-1226 for 2 minutes during the peak of the early phase allergic response showed an immediate decline in lung resistance in all animals following HDM challenge (Figure 2).

<p>Figure 2</p>

Effect of S-1226 on lung resistance in the sheep model of asthma.

Effect of S-1226 on lung resistance in the sheep model of asthma. Changes in lung resistance following treatment with S-1226 in 9 different sheep. The treatment was delivered for 2 minutes and lung resistance was measured immediately, and at 1–10 minutes and 10–20 minutes after treatment cessation. All nine sheep showed an immediate and sustained decline in lung resistance following S-1226 treatment given at the peak of the early phase response to inhaled allergen (HDM).

Treatment with S-1226 compared to the other arms of the study are shown in Figure 3. Lung resistance declined by 50.1% ± 5.5, 47.2% ± 6.2 and 51.8% ± 8.3 (mean ± SE) immediately, 1 to 10 minutes and 10 to 20 minutes after treatment with S-1226 respectively. Treatment with 12% CO2 resulted in declines in lung resistance of 36.9% ± 6.8, 20.6% ± 12.0 and 24.3% ± 28.4 (mean ± SE) immediately, 1 to 10 minutes and 10 to 20 minutes after treatment respectively. Treatment with perflubron + medical air resulted in declines in lung resistance of 24.8% ± 7.5, −1.3% ± 10.7 and −7.2% ± 5.1 (mean ± SE) immediately, 1 to 10 minutes and 10 to 20 minutes after treatment respectively. Treatment with salbutamol resulted in declines in lung resistance of 31.3% ± 6.8, 15.3% ± 7.1 and 14.3% ± 9.6 (mean ± SE) immediately, 1 to 10 minutes and 10 to 20 minutes after treatment respectively. Following inhalation of medical air, lung resistance declined by 23.1% ± 9.7, 16.0% ± 10.8 and 13.1% ± 17.5 (mean ± SE) immediately, 1 to 10 minutes and 10 to 20 minutes after treatment respectively. Lung resistance measured following HDM challenge with no treatment decreased by 1.9% ± 4.7, 24.4% ± 4.2 (mean ± SE) at 1 to 10 minutes and 10 to 20 minutes after treatment respectively.

<p>Figure 3</p>

Comparison between S-1226 and other bronchodilators in the sheep model of asthma.

Comparison between S-1226 and other bronchodilators in the sheep model of asthma. This figure shows the % decline in lung resistance following treatment with S-1226, 12% CO2, perflubron, salbutamol, medical air or no treatment in HDM challenged sheep. Measurements were taken immediately, 1–10 minutes and 10–20 minutes after treatment. Treatment with S-1226 showed significant and sustained declines in lung resistance compared to medical air or no treatment. In addition S-1226 showed a significantly greater decline in lung resistance compared to salbutamol. P-values show significant difference from S-1226; *p <0.05, # p ≤ 0.01.

Inhalation of nebulized S-1226 caused a rapid and sustained decrease in lung resistance during the early phase asthmatic response which was significantly greater than no treatment at 1–10 minutes (p = 0.002) and significantly greater than medical air immediately, 1–10 minutes and 10–20 minutes after treatment (p = 0.027, 0.018 and 0.039 respectively). The effect of S-1226 was significantly greater than salbutamol 1–10 minutes and 10–20 minutes after treatment (p = 0.025 and 0.046 respectively). S-1226 showed a significantly greater decline in lung resistance than perflubron alone immediately, 1–10 minutes and 10–20 minutes after treatment (p = 0.019, 0.002 and 0.012 respectively). Finally, the effect of S-1226 was stronger but not significantly different from CO2 alone immediately, 1–10 minutes and 10–20 minutes after treatment (p = 0.329, 0.124 and 0.319 respectively). The CO2 decline in lung resistance appeared shorter-lasting than the decline observed with S-1226.

3.3 Video-bronchoscopy of S-1226 treatment following MCh challenge

The rapidity of the effect was demonstrated by video-bronchoscopy. MCh challenge resulted in rapid constriction of the segmental and subsegmental bronchi. Without treatment the airway narrowing lasted for at least 20 minutes before a slow natural recovery. Following treatment with a spray of S-1226 there was an immediate re-opening (within 5 seconds) of the MCh-constricted airway (Figure 4). A video recording of this treatment effect can be viewed online under Additional file 1. The effect was sustained during the delivery of S-1226 and up to 1 minute after treatment cessation. After that the airway began to re-constrict. Second and third treatments with S-1226 had identical effects.

<p>Figure 4</p>

Video bronchoscopy of the effect of S-1226.

Video bronchoscopy of the effect of S-1226. Bronchoscopic still images of sheep airways pre and post MCh and seconds after initiating treatment with nebulized S-1226 (arrow heads indicate tissue dye). The video presentation is available online under Additional file 1.

<p>Additional file 1:</p>

Video clip description: the black dot is the stain from the tissue dye. The partially occluded airway that is in the center of the screen begins to dilate immediately after the treatment starts (with the click sound on the video). Note that the adjacent smaller, completely occluded, airways also re-opened with treatment.

Click here for file

3.4 Potential mechanisms of action

Our study did not attempt to determine the mechanism of action of S-1226. The bronchodilatory effect of CO2 has been demonstrated in many mammalian species including cats, rats dogs 19 , 22 as well as sheep and humans However, the literature indicates that it might operate through several distinct mechanisms.

The first mechanism is through a direct physiologic relaxant effect of CO2 on airway smooth muscle 20 22 . The way(s) in which CO2 regulates bronchial smooth muscle tone is not fully understood. Recent in vitro data indicates that part of this effect is mediated by pH dependent and part by pH independent but epithelium dependent mechanisms 22 . Studies in vivo indicate the response (in rats) to inhaled CO2 does not require adrenergic pathways 46 . Fisher and Hansen 27 showed in their study of exercise induced asthma that cholinergic pathways were not involved in the bronchodilatory effects of inhaled CO2. Bronchodilator drugs that use β- adrenergic and cholinergic pathways form the current basis for treating obstructive lung disease.

Inhaled carbon dioxide (5, 10 and 15%) has been shown to reduce total lung resistance induced by intravenous histamine, acetylcholine and serotonin in dogs, cats and rats 19 . Inhaled CO2 has also been shown to reduce total lung resistance induced by pulmonary artery occlusion in cats and dogs 19 . All species studied responded to CO2 but there were small differences in response to the different broncho-constricting agents between species.

Studies by Ingram and colleagues 47 suggest that the bronchodilatory effect of CO2 may be independent of blood PCO2. They studied the effect of varying airway and arterial PCO2 on airway tone in dogs. They showed that low airway PCO2 combined with high arterial PCO2 resulted in a large increase in airway resistance 47 . These findings indicate that CO2 may have unique properties when delivered through the airways and supports the previously cited in vitro work that airway epithelium plays a part in the relaxant response 22 . Finally the rapidity of the response as seen in the sheep video indicates that neural mechanisms are involved. The non-adrenergic-non cholinergic (NANC) pathways are the best candidates for this effect. The NANC system has both broncho-constrictive and bronchodilator components 48 . CO2 alone or S-1226 may activate the bronchodilatory pathways or inhibit the broncho-constrictive pathways. Further work is required to address these questions.

The second mechanism may enhance delivery of CO2 to the airways. It could do this in several ways; first sustained release of CO2 dissolved in perflubron droplets as the droplets evaporate may explain the temporal synergism observed with the combination treatment. Second, because much of S-1226 is in gaseous form, it will be delivered rapidly into obstructed airways by diffusion and possibly through collateral ventilation.

The third mechanism whereby this combination treatment may work is by facilitating penetration and lubrication of mucus plugs, thus enhancing muco-ciliary clearance. We recently reported, using an in vitro system, that mucin plug clearance was significantly enhanced by perflubron 49 .

S-1226 may also lower the surface tension in the inflamed airways. It has been shown that the normal airway is lined by a thin film of endogenous surfactant with a low surface tension 50 . This film is important for maintaining small airway patency at low lung volumes 51 and is abnormal in asthma 52 , 53 .

Finally, carbon dioxide and perfluorocarbons may also be beneficial for their anti-inflammatory properties. Perflubron given in vitro or during partial liquid ventilation exerts an anti-inflammatory effect on alveolar cells 54 , decreases white blood cell counts, 54 , 55 and the pro-inflammatory cytokines IL-1 and IL-6. Perflubron also increases release of the anti-inflammatory chemokine IL-10 54 .

3.5 Strengths and limitations of the animal model

Like with most experimental systems, large animal models of allergic airway disease have both strengths, and also limitations, which need to be recognised when evaluating new therapies for asthma 56 58 . For example, clinically efficacious anti-asthma drugs such as leukotriene LTE4 receptor antagonists, cromolyn and corticosteroids have all been successfully tested in the sheep model of asthma 59 . The success of these drugs is in contrast to the testing of platelet activated factor (PAF) antagonist therapies in sheep. PAF antagonists were shown to alleviate allergic airway responses in sheep 60 , however the positive outcome with these treatments in sheep did not translate to humans giving negative results in clinical trials 61 . Nevertheless, sheep are an appropriate species to investigate the efficacy of the bronchodilator reported here for a number of important reasons. Firstly, the sheep respiratory system is at least comparable to the human system with respect to lung size, lung anatomy and morphology, and the pharmacological and physiological parameters of the ovine lung 57 59 . Pertinent to this study, as the mechanism of the bronchodilator most likely involves both the airway smooth muscle and the intact airway epithelium 22 , is that the arrangement and morphology of ovine airway epithelium 62 and airway smooth muscle down the tracheo-bronchial tree 57 is functionally similar to that observed in human lungs. Thus, the bronchodilator interactions we report here for the sheep model could reasonably translate to the human lung. The other major asset of the sheep model for examining bronchodilator effectiveness relates to the docile nature of sheep, which allows experiments to be ethically conducted in unsedated and unanaesthetised animals 59 , 63 . These anaesthetic and/or sedation agents, if administered as is necessary for behavioural reasons in most other animal species modeling asthma, may otherwise dampen, and thus mask, the bronchodilator responses.

In summary, we provide evidence that treatment with inhaled S-1226 delivered as an aerosol/gas mixture may play an important role in the treatment of acute asthma attacks. We show that perflubron combined with 12% CO2 is a potent airway smooth muscle relaxant in this ovine model of allergic asthma. The response to the combination treatment was rapid and exceeded treatment with medical air (negative control) and salbutamol (positive control) in both amplitude and temporal components. Further work is required to fully evaluate the mechanism(s) of action of this novel therapy.

Competing interests

SolAeroMed Inc is a small biotechnology company founded in partnership with the University of Calgary to develop a novel rescue drug for acute asthma (S-1226). This paper describes pre-clinical animal studies in the development of this drug.

- Dr Tamer El Mays is a co-founder, shareholder and was a temporary employee of SolAeroMed Inc.

- Dr Richard Leigh is a shareholder in SolAeroMed Inc.

- Dr Cora Pieron is a shareholder and part-time employee of SolAeroMed Inc.

- Dr Dennis is a director, co-founder and shareholder in SolAeroMed Inc.

- Dr Francis Green is a director, co-founder and shareholder in SolAeroMed Inc.

- Dr Ken Snibson is a shareholder in SolAeroMed Inc.

- All remaining authors have no competing interests to declare.

Authors’ contributions

Conception and Design: TE, KS, FG, RL. Sheep experiments were conducted by TE, KS, PC, EK and JV. Data acquisition and analysis by EK, JV and GS. Aerosol characterization and delivery system design by CP and JD. Manuscript drafted by TE, revisions and additions by KS, JD, CP, FG, PC, RL, EK, JV, GS. All authors read and approved the final manuscript.

Additional file

<p>Pathogenesis of small airways in asthma</p> Hamid Q Respiration 2012 84 4 11 10.1159/000339550 22759947 <p>Allergic bronchial asthma: airway inflammation and hyperresponsiveness</p> Sugita M Kuribayashi K Nakagomi T Miyata S Matsuyama T Kitada O Intern Med 2003 42 636 643 10.2169/internalmedicine.42.636 12924484 <p>Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma</p> Kelly MM O’Connor TM Leigh R Otis J Gwozd C Gauvreau GM Gauldie J O’Byrne PM J Allergy Clin Immunol 2010 125 349 356 10.1016/j.jaci.2009.09.011 19969339 <p>Fractal geometry of airway remodeling in human asthma</p> Boser SR Park H Perry SF Menache MG Green FH Am J Respir Crit Care Med 2005 172 817 823 10.1164/rccm.200411-1463OC 15976372 <p>Exercise-induced bronchoconstriction</p> Gotshall RW Drugs 2002 62 1725 1739 10.2165/00003495-200262120-00003 12149043 <p>Human rhinovirus infection up-regulates MMP-9 production in airway epithelial cells via NF-{kappa}B</p> Tacon CE Wiehler S Holden NS Newton R Proud D Leigh R Am J Respir Cell Mol Biol 2010 43 201 209 10.1165/rcmb.2009-0216OC 19783786 <p>The global burden of asthma: executive summary of the GINA Dissemination Committee report</p> Masoli M Fabian D Holt S Beasley R Allergy 2004 59 469 478 10.1111/j.1398-9995.2004.00526.x 15080825 <p>Economic burden of asthma: a systematic review</p> Bahadori K Doyle-Waters MM Marra C Lynd L Alasaly K Swiston J FitzGerald JM BMC Pulm Med 2009 9 24 10.1186/1471-2466-9-24 19454036 <p>Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma</p> Ivanova JI Bergman R Birnbaum HG Colice GL Silverman RA McLaurin K J Allergy Clin Immunol 2012 129 1229 1235 10.1016/j.jaci.2012.01.039 22326484 <p>Suboptimal asthma control: prevalence, detection and consequences in general practice</p> Chapman KR Boulet LP Rea RM Franssen E Eur Respir J 2008 31 320 325 10.1183/09031936.00039707 17959642 <p>Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group</p> Boulet LP Becker A Berube D Beveridge R Ernst P CMAJ 1999 161 S1 S61 10906907 <p>Canadian Thoracic Society Asthma Management Continuum–2010 Consensus Summary for children six years of age and over, and adults</p> Lougheed MD Lemiere C Dell SD Ducharme FM Fitzgerald JM Leigh R Licskai C Rowe BH Bowie D Becker A Boulet LP Can Respir J 2010 17 15 24 20186367 <p>Management of severe acute asthma in the emergency department</p> Rowe BH Sevcik W Villa-Roel C Curr Opin Crit Care 2011 17 335 341 10.1097/MCC.0b013e328348bf09 21716106 <p>The FDA and safe use of long-acting beta-agonists in the treatment of asthma</p> Chowdhury BA Dal PG N Engl J Med 2010 362 1169 1171 10.1056/NEJMp1002074 20181964 <p>Acute severe asthma</p> McFadden ER Jr Am J Respir Crit Care Med 2003 168 740 759 10.1164/rccm.200208-902SO 14522812 <p>Severe refractory asthma: an update</p> Wener RR Bel EH Eur Respir Rev 2013 22 227 235 10.1183/09059180.00001913 23997049 <p>Sudden death from asthma in 108 children and young adults</p> Tough SC Green FH Paul JE Wigle DT Butt JC J Asthma 1996 33 179 188 10.3109/02770909609054550 8675497 <p>Management of mechanical ventilation in acute severe asthma: practical aspects</p> Oddo M Feihl F Schaller MD Perret C Intensive Care Med 2006 32 501 510 10.1007/s00134-005-0045-x 16552615 <p>The action of carbon dioxide on constricted airways</p> Astin TW Barer GR Shaw JW Warren PM J Physiol 1973 235 607 623 4772402 <p>Distal airway responses to changes in oxygen and carbon dioxide tensions</p> Duane SF Weir EK Stewart RM Niewoehner DE Respir Physiol 1979 38 303 311 10.1016/0034-5687(79)90056-2 523847 <p>Effects of PCO2, pH and extracellular calcium on contraction of airway smooth muscle from rats</p> Twort CH Cameron IR Respir Physiol 1986 66 259 267 10.1016/0034-5687(86)90078-2 3099356 <p>Carbon dioxide enhances substance P-induced epithelium-dependent bronchial smooth muscle relaxation in Sprague–Dawley rats</p> El Mays TY Saifeddine M Choudhury P Hollenberg MD Green FH Can J Physiol Pharmacol 2011 89 513 520 10.1139/y11-052 21812529 <p>Prevalence of dysfunctional breathing in patients treated for asthma in primary care: cross sectional survey</p> Thomas M McKinley RK Freeman E Foy C BMJ 2001 322 1098 1100 10.1136/bmj.322.7294.1098 11337441 <p>Resistance to breathing during exercise-induced asthma attacks</p> Fisher HK Holton P Buxton RS Nadel JA Am Rev Respir Dis 1970 101 885 896 5419973 <p>Relative contributions of hypocarbia and hyperpnea as mechanisms in postexercise asthma</p> McFadden ER Jr Stearns DR Ingram RH Jr Leith DE J Appl Physiol 1977 42 22 27 833072 <p>Effects of hypercapnia and hypocapnia on respiratory resistance in normal and asthmatic subjects</p> van den Elshout FJ van Herwaarden CL Folgering HT Thorax 1991 46 28 32 10.1136/thx.46.1.28 1908137 <p>Site of action of inhaled 6 per cent carbon dioxide in the lungs of asthmatic subjects before and after exercise</p> Fisher HK Hansen TA Am Rev Respir Dis 1976 114 861 870 984580 <p>Pulmonary applications of perfluorochemical liquids: ventilation and beyond</p> Wolfson MR Shaffer TH Paediatr Respir Rev 2005 6 117 127 10.1016/j.prrv.2005.03.010 15911457 <p>Liquid ventilation - a new way to deliver drugs to diseased lungs?</p> Lehmler HJ Bummer PM Jay M Chemtech 1999 29 7 12 <p>Perfluorocarbon-surfactant interactions: biophysical aspects</p> Schürch S Am Soc Artif Intern Organs 2006 52 487 10.1097/00002480-200607000-00026 <p>Perfluorooctyl bromide (perflubron) attenuates oxidative injury to biological and nonbiological systems</p> Rotta AT Gunnarsson B Fuhrman BP Wiryawan B Hernan LJ Steinhorn DM Pediatr Crit Care Med 2003 4 233 238 10.1097/01.PCC.0000059729.21375.D0 12749658 <p>A liquid perfluorochemical decreases the in vitro production of reactive oxygen species by alveolar macrophages</p> Smith TM Steinhorn DM Thusu K Fuhrman BP Dandona P Crit Care Med 1995 23 1533 1539 10.1097/00003246-199509000-00014 7664556 <p>Perfluorocarbon protects lung epithelial cells from neutrophil-mediated injury in an in vitro model of liquid ventilation therapy</p> Varani J Hirschl RB Dame M Johnson K Shock 1996 6 339 344 10.1097/00024382-199611000-00007 8946649 <p>The combination of partial liquid ventilation and inhaled nitric oxide in the severe oleic acid lung injury model</p> Uchida T Nakazawa K Yokoyama K Makita K Amaha K Chest 1998 113 1658 1666 10.1378/chest.113.6.1658 9631808 <p>Differential impact of perfluorochemical physical properties on the physiologic, histologic, and inflammatory profile in acute lung injury</p> Shashikant BN Miller TL Jeng MJ Davis J Shaffer TH Wolfson MR Crit Care Med 2005 33 1096 1103 10.1097/01.CCM.0000163218.79770.29 15891342 <p>Dose response to aerosolized perflubron in a neonatal swine model of lung injury</p> Kandler MA von der Hardt K Gericke N Chada M Dotsch J Rascher W Pediatr Res 2004 56 191 197 10.1203/01.PDR.0000132667.47744.F4 15181181 <p>Comparison of aerosol therapy with different perfluorocarbons in surfactant-depleted animals</p> von der Hardt K Kandler MA Brenn G Scheuerer K Schoof E Dotsch J Rascher W Crit Care Med 2004 32 1200 1206 10.1097/01.CCM.0000124876.31138.F6 15190973 <p>Induction of allergic inflammation in the lungs of sensitized sheep after local challenge with house dust mite</p> Bischof RJ Snibson K Shaw R Meeusen EN Clin Exp Allergy 2003 33 367 375 10.1046/j.1365-2222.2003.01534.x 12614452 <p>Airway remodelling and inflammation in sheep lungs after chronic airway challenge with house dust mite</p> Snibson KJ Bischof RJ Slocombe RF Meeusen EN Clin Exp Allergy 2005 35 146 152 10.1111/j.1365-2222.2005.02137.x 15725184 <p>Respiratory therapy equipment: Part 1-Nebulizing systems and their components</p> European Nebulizer Standard: EN 13544–1:2007+A1:2009 2009 1 43 <p>Quantification of total sheep IgE concentration using anti-ovine IgE monoclonal antibodies in an enzyme immunoassay</p> Shaw RJ McNeill MM Gatehouse TK Douch PG Vet Immunol Immunopathol 1997 57 253 265 10.1016/S0165-2427(97)00010-X 9261963 <p>Oesophageal techniques for deriving the lung dynamics of quietly breathing sheep</p> Koumoundouros E Snibson K Mareels IY Conf Proc IEEE Eng Med Biol Soc 2008 2008 2435 2438 19163194 <p>Characterization of a late phase pulmonary response after antigen challenge in allergic sheep</p> Abraham WM Delehunt JC Yerger L Marchette B Am Rev Respir Dis 1983 128 839 844 6638671 <p>Tachykinin-induced bronchoconstriction in sheep is NK-1 receptor mediated and exhibits tachyphylaxis</p> Rice AJ Reynolds PN Reynolds AM Holmes MD Scicchitano R Respirology 2001 6 113 123 10.1046/j.1440-1843.2001.00315.x 11422890 <p>Estimating respiratory mechanics in the presence of flow limitation</p> Bijaoui E Tuck SA Remmers JE Bates JH J Appl Physiol 1999 86 418 426 10.1063/1.370746 9887156 <p>Investigations of mechanisms of carbon dioxide-induced bronchial smooth muscle relaxation</p> Choudhury P El Mays T Snibson K Wilson R Leigh R Dennis J Nelson DE Green FHY Am J Respir Crit Care Med 2012 185 A2848 <p>Effects of airway versus arterial CO2 changes on lung mechanics in dogs</p> Ingram RH Jr J Appl Physiol 1975 38 603 607 1141090 <p>Beta 2- but not beta 3-adrenoceptors mediate prejunctional inhibition of non-adrenergic non-cholinergic contraction of guinea pig main bronchi</p> Ten Berge RE Weening EC Roffel AF Zaagsma J Eur J Pharmacol 1995 275 199 206 10.1016/0014-2999(94)00771-X 7796855 <p>Perflubron enhances mucin plug clearance <it>in vitro</it> in the presence of natural surfactant</p> Al-Saiedy M Nelson E El Mays T Amrein M Green F Eur Respir J 2013 42 Suppl. 57 124s ERS International Congress, Barcelona, Spain. Ref Type: Abstract <p>Alveolar surface forces and lung architecture</p> Bachofen H Schurch S Comp Biochem Physiol A Mol Integr Physiol 2001 129 183 193 10.1016/S1095-6433(01)00315-4 11369543 <p>Surface activity in situ, in vivo, and in the captive bubble surfactometer</p> Schurch S Bachofen H Possmayer F Comp Biochem Physiol A Mol Integr Physiol 2001 129 195 207 10.1016/S1095-6433(01)00316-6 11369544 <p>Compositional and functional changes of pulmonary surfactant in a guinea-pig model of chronic asthma</p> Cheng G Ueda T Sugiyama K Toda M Fukuda T Respir Med 2001 95 180 186 10.1053/rmed.2000.1012 11266234 <p>Surfactant and allergic airway inflammation</p> Winkler C Hohlfeld JM Swiss Med Wkly 2013 143 w13818 23896983 <p>Partial liquid ventilation decreases the inflammatory response in the alveolar environment of trauma patients</p> Croce MA Fabian TC Patton JH Jr Melton SM Moore M Trenthem LL J Trauma 1998 45 273 280 10.1097/00005373-199808000-00012 9715184 <p>Partial liquid ventilation reduces pulmonary neutrophil accumulation in an experimental model of systemic endotoxemia and acute lung injury</p> Rotta AT Steinhorn DM Crit Care Med 1998 26 1707 1715 10.1097/00003246-199810000-00026 9781729 <p>Use of alternative animals as asthma models</p> Kirschvink N Reinhold P Curr Drug Targets 2008 9 470 484 10.2174/138945008784533525 18537586 <p>Airway disease: the use of large animal models for drug discovery</p> Van der Velden J Snibson KJ Pulm Pharmacol Ther 2011 24 525 532 10.1016/j.pupt.2011.02.001 21356324 <p>Animal models of asthma</p> Zosky GR Sly PD Clin Exp Allergy 2007 37 973 988 10.1111/j.1365-2222.2007.02740.x 17581191 <p>Modeling of asthma, COPD and cystic fibrosis in sheep</p> Abraham WM Pulm Pharmacol Ther 2008 21 743 754 10.1016/j.pupt.2008.01.010 18339565 <p>YM461, a PAF antagonist, blocks antigen-induced late airway responses and airway hyperresponsiveness in allergic sheep</p> Tomioka K Garrido R Ahmed A Stevenson JS Abraham WM Eur J Pharmacol 1989 170 209 215 10.1016/0014-2999(89)90541-4 2620695 <p>Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy</p> Kasperska-Zajac A Brzoza Z Rogala B Recent Pat Inflamm Allergy Drug Discov 2008 2 72 76 10.2174/187221308783399306 19075994 <p>Tracheobronchial epithelium of the sheep: III. Carbohydrate histochemical and cytochemical characterization of secretory epithelial cells</p> Mariassy AT St George JA Nishio SJ Plopper CG Anat Rec 1988 221 540 549 10.1002/ar.1092210110 3389536 <p>Chronic airway disease: deteriorating pulmonary function in sheep associated with repeated challenges of house dust mite</p> Koumoundouros E Bischof RJ Meeusen EN Mareels IM Snibson KJ Exp Lung Res 2006 32 321 330 10.1080/01902140600916960 17060175